Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205471295> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W4205471295 abstract "Abstract Background We identified AD‐associated Aβ pathology in ocular lenses from patients with neuropathologically‐confirmed AD but not non‐AD neurodegenerative diseases or normal aging (Goldstein et al., Lancet , 2003). We reported identical early‐onset Aβ lens pathology in Down syndrome (Moncaster et al., 2010). In Framingham Eye Study participants, we found that AD phenotypes are expressed years‐to‐decade+ earlier in lens than brain and identified a new GWAS‐significant AD risk gene (CTNND2, δ‐catenin) that modulates Aβ expression in lens and brain (Jun et al., 2012). This research spurred development of a novel drug‐device eye scanner (Sapphire II‐Aftobetin system) that combines a topically‐applied Aβ‐binding fluorescent ligand (Aftobetin) with a purpose‐designed fluorescence laser eye scanner (FLES). Sapphire II detects lens Aβ with high reliability, sensitivity, specificity, and SNR. Clinical testing showed that Sapphire II distinguishes subjects with probable AD from normal controls (Kerbage et al., Front Neurol, 2013; Am J Alz Dis Dement, 2015). This study evaluated Sapphire II compared to amyloid PET scans in subjects with MCI or early AD. Method 48 participants: 28 MCI, 16 mild AD, 4 normal controls (NC); age range: 60‐85 years. MCI and AD subjects underwent cognitive testing and amyloid PET scans (Florbetapir, Amyvid). The Sapphire II system detects a highly‐specific fluorescent lifetime decay spectroscopic signature associated with bound Aftobetin‐Aβ complexes in the lens. Each scan requires <1 sec. Multiple scans can be acquired in a single sitting. Result 43 subjects have been evaluated to date. No serious adverse events have been reported. Subject correlation with amyloid PET yielded 75% specificity, 100% sensitivity, 95% accuracy, 94% PPV, and 100% NPV. To date, there has been no subject in which Sapphire II was negative and amyloid‐PET was positive. Of the 39 Sapphire II‐positive subjects, 26 were amyloid‐PET positive. Evaluation of individual PET scans and cognitive testing suggest that lens amyloid burden assessed by Sapphire II eye scan is more sensitive than amyloid PET compared to clinical criteria. Conclusion The Sapphire II‐Aftobetin drug‐device combination platform provides a safe, sensitive, and convenient screening tool for rapid non‐invasive evaluation of AD‐associated β‐amyloid (Aβ) burden in subjects with MCI and mild AD." @default.
- W4205471295 created "2022-01-25" @default.
- W4205471295 creator A5021670944 @default.
- W4205471295 creator A5023026853 @default.
- W4205471295 creator A5036903366 @default.
- W4205471295 creator A5045045118 @default.
- W4205471295 creator A5087033653 @default.
- W4205471295 date "2021-12-01" @default.
- W4205471295 modified "2023-10-17" @default.
- W4205471295 title "Pre‐pivotal clinical study of β‐amyloid in the ocular lens by Sapphire II‐aftobetin eye scan: Correlation with amyloid PET imaging in mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD)" @default.
- W4205471295 doi "https://doi.org/10.1002/alz.055617" @default.
- W4205471295 hasPublicationYear "2021" @default.
- W4205471295 type Work @default.
- W4205471295 citedByCount "0" @default.
- W4205471295 crossrefType "journal-article" @default.
- W4205471295 hasAuthorship W4205471295A5021670944 @default.
- W4205471295 hasAuthorship W4205471295A5023026853 @default.
- W4205471295 hasAuthorship W4205471295A5036903366 @default.
- W4205471295 hasAuthorship W4205471295A5045045118 @default.
- W4205471295 hasAuthorship W4205471295A5087033653 @default.
- W4205471295 hasConcept C118487528 @default.
- W4205471295 hasConcept C142724271 @default.
- W4205471295 hasConcept C2779134260 @default.
- W4205471295 hasConcept C2779483572 @default.
- W4205471295 hasConcept C2984915365 @default.
- W4205471295 hasConcept C71924100 @default.
- W4205471295 hasConceptScore W4205471295C118487528 @default.
- W4205471295 hasConceptScore W4205471295C142724271 @default.
- W4205471295 hasConceptScore W4205471295C2779134260 @default.
- W4205471295 hasConceptScore W4205471295C2779483572 @default.
- W4205471295 hasConceptScore W4205471295C2984915365 @default.
- W4205471295 hasConceptScore W4205471295C71924100 @default.
- W4205471295 hasIssue "S5" @default.
- W4205471295 hasLocation W42054712951 @default.
- W4205471295 hasOpenAccess W4205471295 @default.
- W4205471295 hasPrimaryLocation W42054712951 @default.
- W4205471295 hasRelatedWork W1972349970 @default.
- W4205471295 hasRelatedWork W2063138855 @default.
- W4205471295 hasRelatedWork W2106668145 @default.
- W4205471295 hasRelatedWork W2112529311 @default.
- W4205471295 hasRelatedWork W2150765520 @default.
- W4205471295 hasRelatedWork W2335556309 @default.
- W4205471295 hasRelatedWork W2408175884 @default.
- W4205471295 hasRelatedWork W4250829769 @default.
- W4205471295 hasRelatedWork W4362633500 @default.
- W4205471295 hasRelatedWork W4366447851 @default.
- W4205471295 hasVolume "17" @default.
- W4205471295 isParatext "false" @default.
- W4205471295 isRetracted "false" @default.
- W4205471295 workType "article" @default.